Medical Research Council

Other

Cancer Research Campaign Technology Limited

The Institute of Cancer Research: Royal Cancer Hospital

Genetic Therapy, Inc.

Robin Anthony Weiss

Francois-Loic Cosset

Yasuhiro Takeuchi

Mary Katharine Collins

Stephen James Russell

Michael Pensiero

Frances Joanne Morling

Jonathan Paul Stoye

Frances Joanne Bullough

Francois-Lois Cosset

Mary Katherine Collins

Mary K L Collins

Retroviral vectors which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.

Retroviral vectors produced by producer cell lines resistant to lysis by human serum

Expression systems

The present invention is based upon the finding that porcine endogenous retroviruses exist in two different subtypes, which we have termed PERV-A and PERV-B. The differences are reflected in sequence divergence in the envelope genes, and these differences may be used to provide nucleic acid and antibody probes which can distinguish between the two subtypes. This allows patterns of subtype transmission between cells, particularly porcine to human cells, to be monitored.

Detection of retroviral subtypes based upon envelope specific sequences

The invention relates to a recombinant viral particle capable of delivering a nucleic acid to mammalian cells, the particle including a member of a first specific binding pair capable of binding to a first receptor expressed on the surface of a cell so as to cause infection thereof, and a surface-exposed member of a second specific binding pair capable of binding to a second receptor generally not expressed on the surface of the cell, such that binding of the viral particle to the second receptor via the member of the second specific binding pair inhibits infection of the cell by the viral particle.

Delivery of nucleic acids

Retroviral which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.

Retroviral vectors produced by producer cell lines resistant to lysis by

Growing community of inventors

London, United Kingdom

Robin Anthony Weiss